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EFFECT OF ORAL AND TOPICAL 17a-METHYL-B-NORTESTOS-
TERONE ON SEBTJM PRODUCTION AND PLASMA
TESTOSTERONE*
JOHN S. STRAUSS, M.D., PETER E. POCHI, M.D., INDER H. SARDA,
M.Sc. AND HERBERT H. WOTIZ, PaiD.
The systemic administration of estrogen in
adequate dosage has been shown to effect
significant reduction of sebaceous gland ac-
tivity and to be useful in the therapy of acne
in women (1). However, when administered to
men, doses necessary to achieve sebaceous
gland suppression almost invariably result in
undesirable feminizing effects. Since the seba-
ceous glands arc androgen-sensitive, substances
having anti-androgenic action might be expected
to counteract the peripheral stimulatory ef-
fect of androgcn on the sebaceous gland. This
report will detail studies on the effect of l7ot-
mcthyl-B-nortestosteronc, a synthetic steroid
with anti-androgenic activity (2—4), on sebum
production and plasma testosterone levels in
man.
MATERIAL AND METHODs
Studies were carried out in twenty-five adult
males and nine adult females. The men were
normal volunteer subjects. Six of the women were
normal subjects; three were patients with idio-
pathic hirsutism.t Most of the subjects, with the
exception of those with hirsutism, had no skin dis-
order, although a few individuals had mild acne.
The drug was administered both orally and
topically. The first trials with the oral route con-
sisted of the administrat.ion of increasing incre-
ments of the drug in dosages of 50 to 600 mg per
day. In later trials, the daily oral dose was 300
mg. In this report, sebum production data are
given only for those subjects who received 300
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milligrams or more per day for at least a 5-week
period. Data on subjects receiving lesser amounts
of the drug are not included herein.
For topical use, the anti-androgen was applied in
a creani baset to the forehead twice daily. In one
instance a 2% cream was used alone, and in four
instances a 2% cream was used first, followed with-
out a rest period by the application of a 10%
cream. In all other cases a 10% cream was used
throughout the treatment period. The data for
both concentrations have been grouped together
since there was no apparent difference in response
between the two concentrations used.
Sebum production was measured by the previ-
ously described technic which is in use in our lab-
oratory (5). This measures the amount of bpid
delivered to a measured area of the forehead over
a 3-hour period. The test area was the site of topi-
cal application; treatment was omitted on the
morning of testing. Three or more control tests
were done prior to the drug trial in each subject,
and the mean for all of these control values was
calculated for each subject. Measurements of
sebum production were done at varying intervals
during drug administration. In most cases testing
was done once a week. In each individual a mean
sehum value for the drug trial period was calcu-
lated, based only on tests obtained after the fourth
week of treatment. Earlier values were excluded
since the response of the sebaceous glands was
slow. Even with sebum-suppressive doses of estro-
gen there is usually a comparable latent period
beforeshaceous gland inhibition occurs (1).
The concentration of free plasma testosterone
was measured in 16 male subjects before and after
t The percentage composition of the two topi-
cal preparations was as follows:
10% 2%
17a-Methyl-B-nortestosterone 10.000 2.00
(SK&F 7690)
Sodium lauryl sulfate, USP 0.450 0.49
Triethanolamine, N.F. 0.630 0.69
Methylparaben, USP 0.135 0.15
Propylparaben, USP 0.018 0.02
Propylene glycol, USP 9.000 9.78
Stearic acid, TJSP 9.000 9.78
Cetyl alcohol, NF 3.150 3.42
Wool fat, USP 0.450 0.49
Purified water, USP 67.167 73.18
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of the steroid. In brief, the specific details of the
method follow.
Twenty to thirty ml of alkalinized plasma were
_________ ________ _________________ ______________
extracted three times with diethyl ether, and the
protein was precipitated out in 70% methanol at
—10° C. Defatting was accomplished by partition-
ing between 70% methanol and light petroleum
ether, and the steroid was re-extracted with di-
ethyl ether. Thin-layer chromatography of the
dried ether extract was carried out on a silica gel
C-plato in two successive systems (system I:
henzene:ethyl acetate 60:40; system II: ehloro-
form:aeetone 95:5). The steroid was eluted from
the silica gel with benzene/water partitioning.
After drying in a desiccator for 4—5 hours, the
residue was reacted with hexamethyldisilazane
and trimethylelilorosilane in hexane either over-
night at room temperature or for 1 hour at 70° C
(7). The mixture, in an appropriate volume of
hexane, was then injected into a gas ehromatograph
_______________________________________________ equipped with a flame ionization detector. A
6 ft x 4 mm glass column packed with 2% XE-GO
on Diatoport S was used. The mean recovery of
the steroid prior to gas-liquid chromatography was
70% as determined by the addition of approxi-
mately 10,000 rpm of testosterone 1,2-He to the
plasma prior to extraction. A correction for the
loss of testosterone was applied to the calcula-
tions.
Decrease \\Tith this method, it is possible to detect 0.01
_______________
sg of pure testosterone TMSi. This allows for the
measurement of 0.30 g of testosterone/100 ml
_________
plasma with 90% accuracy using 20 ml of plasma.
For lower concentrations of testosterone it would
ho necessary to use 25—30 ml of plasma.
The specificity of the method is based on the
fact that all other neutral steroids are completely
separated either by thin-layer or gas chromatog-
raphy. Also quantitative results obtained on polar
and non-polar (SE-30, XE-GO) phases were within(8).
The precision of the method was assessed by 6
replicate analyses on a 20 ml pool of male plasma.
The mean concentration of testosterone in this
pooled specimen was found to be 0.58 0.06 cg/
100 ml
Statistical analyses for both sebum production
_____________________
and plasma testosterone measurements were done
by the method of paired comparison.
the period of drug administration. Five of those
subjects received the drug orally, and 11 were
treated topically. A modification of the method of
Guerra-Gareia et of. (6) was used for measuring
plasma testosterone levels. It was necessary to
introduce a second thin-layer chromatogram for
the preliminary separation of the steroids from
other contaminants. The steroid was converted to
its trimethylsilyl ether (TMSi) prior to gas-liquid
chromatography. The use of the TMSi ether im-
proves the separation of closely related steroids
such as testosterone and epitestosterone, increases
the detector response and increases the volatility
TABLE I
Effect of oral administration of 17a-methyl-B-
nortestosterone on sebum production in men
Sebum prsduction
Subject Weeks (mg sebum/15 sq
cm/S Isours)
Decrease
(%)
Control Treatment
1 9 3.41 2.72 20.2
2 14 3.09 2.60 15.9
3 9 2.16 1.96 9.3
4 7 1.90 1.58 16.8
5 9 1.38 1.27 8.0
Mean 2.39 2.03 15.1
(P < .05)
Effect of oral
TABLE II
administration of 17a-methyl-B-
nortestoserone on sebum production in women
Sebum production
(mg sebum/lO sq
cm/S hnurs)
Control I reatment
Subject
A
B
C
D*
E*
F
G
H
1*
Weeks
9
9
9
5
71
9
9
8
53
5.08
2.91
2.84
2.79
2.55
2.10
1.91
1.63
1.54
2.78
2.73
1.92
2.02
1.20
2.02
1.79
1.12
.58
45.3
6.2
32.4
27.6
52.9
3.8
6.3
31.3
62.3
Mean 2.59 1.80 30.5
(P < .01)
* Jdiopathio hirsutism.
EESULT5
Sebum production. Table I summarizes the
effect on sebum production in male subjects
following the oral administration of 17a-methyl-
B-nortestosterone. The drug produced a var-
iable decrease in sebum production, from 8.0%
to 20.2%. Nonetheless, the average reduction of
15.1% for tIns group of five subjects was statisti-
cally significant (p < .05).
In Table II, sebum production data are
presented for the nine women who were given
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TABLE IV
Changes in plasma testosterone following oral
administration of l7ca-methyl-B-nortestosterone
in men
the drug orally. There was considerable varia-
tion in the suppressive response, with the fall in
sebum ranging from 3.8% to 62.3%. The aver-
age decrease in sebum production (30.8%) was
twice that seen in the male subjects. However,
exact comparison is not possible as the two
women who showed the greatest effect were
treated for much longer periods of time (53 and
71 weeks).
The topical application of 17a-methyl-B-
nortestosterone, as shown in Table III, resulted
in a decrease in sebum production in the ma-
jority of subjects with 11 of 21 showing a more
TABLE III
Effect of topical application of l7e-methyl-B-
nortestosterone on sebum production in men
Plasma
testosterone
Decrease
Subject Weeks in sebumproduction(%)
pg/100 in! Difference
Control
1 9 20.2 .34 .28 — .06
4 7 16.8 .46 .16 — .30
2 14 15.9 .36 .06 — .30
3 9 9.3 .45 .28 — .17
5 9 8.0 .52 .29 —.23
25 3 * 1.14 .83 —.31
Mean .55 .32 — .23
(P < .01)Sebum production
Subject Weeks (mg sebiun/lO sq Decrease
cm/3 hours) (%)
Control Treatment
6 11 4.62 3.47 24.9
7 20 3.61 2.39 33.8
8 11 3.57 3.99 —
9 11 3.56 3.71 —
10 11 3.21 2.46 23.4
11 18 3.05 3.31 —
12 10 2.93 1.96 33.1
13 16 2.74 2.02 26.3
14t 15 2.65 2.10 20.8
1St 21 2.52 1.79 29.0
3 10 2.35 2.42
l6 21 2.10 1.54 26.7
17 17 2.08 2.51
18 17 2.07 2.38 —
19 20 2.00 1.89 5.5
20t 21 1.97 1.62 17.8
21 20 1.65 1.82 —
5 13 1.64 0.95 42.1
22 13 1.54 0.83 46.1
23 14 1.39 1.31 5.8
24 13 1.33 0.55 58.6
Mean 2.50 2.14 14.4
(P < .01)
* Case 7 received a 2% cream throughout the
treatment program.
t Cases 14, 15, 16, 20 received a 2% cream for the
first 7z weeks of the treatment program and then
received a 10% cream for the rest of the treatment
schedule.
* Subject received only 3 weeks of treatment at
300 mg/day level.
than 20% suppression. The mean per cent
decrease of 14.4%, which was statistically sig-
nificant, was similar to that produced with sys-
temic administration of the drug in men. How-
ever, since the size of the two groups is unequal,
no conclusion on comparable activity of the
drug in relation to the mode of administration
is warranted from these data. One subject
('13) was treated with a placebo cream base
for eight weeks prior to the time that the active
cream was first applied. There was no change
in sebum output during the placebo period,
whereas suppression occurred when the active
cream was applied.
In six subjects the active cream was applied
to one side of the forehead, and sebum pro-
duction was measured on the treated as well
as on the contralateral untreated side of the
forehead. In one subject ($12) a fall of sebum
output of 33.1% occurred on the treated side
(Table III) with a decrease of only 6.1% on
the untreated side. In the remaining five
cases, (11, 17, 18, 19, 21) there was no sup-
pression of sebum output in either site.
Plasma testosterone levels. All of the men
to whom 17a-methyl-B-nortestosterone was
given orally showed a decrease in the concen-
tration of plasma testosterone (Table IV).
There was much more variability in plasma
testosterone levels after topical therapy, a!—
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TABLE V
Changes in plasma testosterone concentration
following topical applicotion of 17cr-methyl-B-
norlesloslerone in men
Maan .59 .46 — .13
(P < .05)
though most of the men in this group also
showed a decrease in plasma testosterone (Table
V). It should be noted that the subjects receiv-
ing topical therapy were treated for longer pe-
riods of time than those receiving systemic ther-
apy. Yet, the per cent reduction in testosterone
in the latter group was twice that of the former
group. The changes in plasma testosterone, how-
ever, could not he correlated with the effect ou
sehum production in either group.
DISCUSSION
A decrease in sebum production has been
reported previously in women receiving 17a-
methyl-B-nortestosterone in a dosage of 400 mg
daily (9). Sebaceous gland suppression was ob-
served in 7 of 11 women so treated and occurred
within 10 days from the onset of therapy. When
sebum suppression was observed in our studies,
it did not occur this rapidly.
To our knowledge, this is the first anti-
androgen that has produced a decrease in sebum
production after topical application. However,
while individual responses were occasionally
quite striking, the overall effect on sebum pro-
duction was quite variable, with only a 14.4%
average suppression of sebum output. A placebo
cream was used only once: no decrease in sebum
production was observed whereas the same
individual responded on two other occasions to
active cream.
The treatment trials in which the active
cream was applied to one side of the forehead
and sebnm production measured on both sides
were designed to determine whether this agent
had a direct local effect. Unfortunately, only
one of the subjects in this group showed a de-
crease in sebum production on the treated side.
Thus, there were insufficient positive data to
determine the drug's site of action. Similarly,
the data on the effect upon plasma testosterone
which might also have provided information in
this regard, are somewhat difficult to interpret
with conclusiveness. A decrease in plasma tes-
tosterone level occurred after both systemic
and local treatment, although the decrease in
the topically treated group was not as great or
as consistent as in those subjects given oral
drug. These observations suggest that this
anti-androgen can exert its effect systemically
as well as locally. It is interesting to note that
on the basis of studies on sebum production in
rats, Ebling has concluded that 17a-methyl-B-
nortestosterone has only peripheral anti-andro-
gen activity (10).
The drug had no effect on menses. While no
hair measurements were made, the two women
who were treated for long periods of time (53
and 71 weeks) did note lessening of their hir-
sutism. In the men, no side effects were ob-
served. Caplan (11) reported the occurrence of
gyneeomastia in 12 of 13 males treated for acne
with oral 17a-methyl-B-iortestosterone. It was
observed to appear on the average 3—4 months
after starting treatment. In our study gyneco-
mastia was not seen in the men receiving the
drug orally possibly because all but one of
them received medication for 9 weeks or less.
SUMMAnT
The oral administration of the anti-androgen,
17a-methyl-B-norteatosterone, in a dosage of
300 mg daily, resulted in a significant inhibition
of sebum production in both men and women.
In men, the topical application of 2% or 10%
1 7ce-methyl-B-norteatosterone also suppressed
sebum production. A decrease in plasma tes-
tosterone levels was observed in men treated
either topically or systemically with this anti-
androgen.
Subiect Weeks
Plasma
testosterone
pg/ISO ml
control Treat-
Decrease
in sebum
production(%)
33.8
29.0
26.7
26.3
24.9
23.7
20.8
17.8
None
None
7
15
16
13
6
10
14
20
8
9
20
21
21
16
11
11
15
21
11
11
Difference
None
—
.07
—
.27
—
.31
+ .07
—
.41
—
.07
+ .02
—
.08
—
.22
.21
.58
.59
.75
.54
1.08
.61
.32
.52
.71
.21
.51
.32
.44
.61
.67
.54
.34
.44
.49
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